July 25, 2019 Impact: High Bristol-Myers Squibb has provided updates on Part 1a and Part 2 of the Phase 3 CheckMate -227 study of Opdivo in 1L NSCLC.
Part 1a, which evaluated Opdivo and Yervoy vs. chemotherapy, met the co-primary…
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2019-08-02 16:42:412019-08-02 16:42:53Phase 3 CheckMate - 227 update in 1L NSCLC: survival benefit with Opdivo/Yervoy but not Opdivo/chemotherapy
July 23, 2019 Impact: High Zolgensma is approved for the treatment of pediatric patients less than 2 years of age with SMA including those who are pre-symptomatic at diagnosis.
Zolgensma is designed to address the genetic root cause…
July 23, 2019
Impact: Moderate BeiGene has announced that the China NMPA (National Medical Products Administration) has granted Priority Review status to the sNDA for tislelizumab (anti-PD-1; Fc-engineered) for patients with previously…
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2019-07-23 15:25:352019-07-23 15:26:36BeiGene’s Tislelizumab Granted Priority Review in China for Urothelial Carcinoma
June 18, 2019
Impact Level: High FDA has granted accelerated approval to Keytruda (pembrolizumab) monotherapy for 3L treatment of metastatic SCLC. According to Keytruda’s revised label, it is indicated for use after platinum-based…
May 20, 2019 Impact Level: Moderate Merck has announced that its Phase 3 KEYNOTE-119 trial assessing Keytruda (pembrolizumab) monotherapy compared to chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine) in 2L and 3L metastatic…
May 14, 2019 Impact Level: Moderate The LIBERTY 1 study met its primary efficacy endpoint with 73.4% of women receiving once daily oral relugolix combination therapy achieving the responder criteria compared with 18.9% of women receiving…
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2019-05-20 17:24:162019-05-20 18:04:29Myovant Reports Phase 3 Data of Relugolix in Uterine Fibroids